Table 2 Univariate analysis risk factor for colistin-resistance carbapenemase-producing Enterobacterales
Variables | Total | Colistin resistance | p-value | |
|---|---|---|---|---|
Yes | No | |||
n = 32 | n = 82 | |||
n = 114 | ||||
n (%) | n (%) | n (%) | ||
Invase procedures | ||||
Mechanical ventilator | 74 (64.91) | 23 (71.88) | 51 (62.2) | 0.331 |
Central venous catheter | 76 (67.26) | 21 (67.74) | 55 (67.07) | 0.946 |
Urinary catheter | 90 (79.65) | 25 (78.13) | 65 (80.25) | 0.801 |
Gastrostomy | 16 (14.55) | 5 (16.67) | 11 (13.75) | 0.763 |
Tracheostomy | 46 (40.35) | 16 (50) | 30 (36.59) | 0.19 |
Nasogastric tube | 74 (64.91) | 18 (56.25) | 56 (68.29) | 0.226 |
Hemodyalisis catheter | 25 (22.12) | 13 (41.94) | 12 (14.63) | 0.002a |
Surgery | 44 (38.94) | 12 (38.71) | 32 (39.02) | 0.976 |
Total parenteral Nutrition | 24 (21.43) | 2 (6.67) | 22 (26.83) | 0.021a |
Peripherical catheter | 87 (77.68) | 19 (63.33) | 68 (82.93) | 0.027a |
Antimicrobials | ||||
β-lactam-inhibitors | 31 (27.19) | 13 (40.63) | 18 (21.95) | 0.044a |
Cephalosporins | 32 (28.07) | 8 (25) | 24 (29.27) | 0.649 |
Aztreonam | 2 (1.75) | 1 (3.13) | 1 (1.22) | 0.484 |
Carbapenem | 56 (49.12) | 16 (50) | 40 (48.78) | 0.907 |
Quinolone | 27 (23.68) | 7 (21.88) | 20 (24.39) | 0.777 |
Vancomycin | 44 (38.6) | 10 (31.25) | 34 (41.46) | 0.314 |
Clindamycin | 17 (15.18) | 5 (16.13) | 12 (14.81) | 1.000 |
Doxycycline | 6 (5.26) | 1 (3.13) | 5 (6.1) | 1.000 |
Tigecycline | 11 (9.65) | 4 (12.5) | 7 (8.54) | 0.499 |
Colistin | 15 (13.16) | 6 (18.75) | 9 (10.98) | 0.355 |
Aminoglycosides | 20 (17.54) | 5 (15.63) | 15 (18.29) | 0.736 |
Trimethoprim/sulfamethoxazole | 9 (7.89) | 2 (6.25) | 7 (8.54) | 1.000 |
Metronidazol | 13 (11.4) | 3 (9.38) | 10 (12.2) | 1.000 |
Macrolides | 15 (13.51) | 5 (15.63) | 10 (12.66) | 0.761 |
Linezolid | 10 (9.01) | 4 (12.5) | 6 (7.59) | 0.47 |
Microorganism isolated previous CR-CPE | ||||
ESBL E. coli | 5 (4.39) | 0 (0) | 5 (6.1) | 0.32 |
ESBL K. pneumoniae | 2 (1.75) | 0 (0) | 2 (2.44) | 1.00 |
Carbapenem-resistant A. baumannii | 5 (4.39) | 4 (12.5) | 1 (1.22) | 0.021a |
Methicillin-resistant S. aureus | 7 (6.14) | 3 (9.38) | 4 (4.88) | 0.399 |
E. coli | 3 (2.63) | 1 (3.13) | 2 (2.44) | 1.00 |
K. pneumoniae | 2 (1.75) | 0 (0) | 2 (2.44) | 1.00 |
A. baumannii | 4 (3.51) | 0 (0) | 4 (4.88) | 0.20 |
Methicillin- susceptible S. aureus | 1 (0.88) | 0 (0) | 1 (1.22) | 1.00 |
P. aeruginosa | 1 (0.88) | 0 (0) | 1 (1.22) | 1.00 |
E. cloacae | 2 (1.75) | 0 (0) | 2 (2.44) | 1.00 |
Otros | 28 (24.56) | 7 (21.88) | 21 (25.61) | 0.677 |
Previous exposures within 3 months | ||||
Hospitalization | 47 (41.96) | 14 (43.5) | 33 (41.25) | 0.809 |
Inmunosupression | 21 (18.58) | 8 (25.0) | 13 (16.05) | 0.270 |
Intubation | 17 (15.18) | 4 (12.5) | 13 (16.25) | 0.774 |
Invasive procedures | 21 (18.58) | 4 (12.5) | 17 (20.99) | 0.296 |
Hemodialysis | 9 (8.04) | 6 (18.75) | 3 (3.75) | 0.016a |